Literature DB >> 15009768

Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization.

Robert E Eckart1, Catherine F T Uyehara, Eric A Shry, James L Furgerson, Richard A Krasuski.   

Abstract

BACKGROUND: Extracellular matrix remodeling is a component of coronary artery disease (CAD). Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix degradation. The extrapolation of the role MMPs play in the clinical setting of acute coronary syndromes has not yet been defined.
METHODS: Samples from 100 subjects undergoing cardiac catheterization were analyzed for serum levels of MMP-1, MMP-2, and MMP-9. These markers were assessed before, immediately after, and 24 hours after cardiac catheterization. Relationships among MMP levels, baseline characteristics, angiography findings and clinical course were assessed.
RESULTS: Comparing subjects with myocardial infarction versus those without, baseline MMP-1 levels were not different at baseline but increased during the hospital stay, MMP-2 levels were higher at baseline and throughout the monitoring period and MMP-9 levels lower and decreased over time. MMP-1 was higher 24 hours after catheterization in subjects undergoing revascularization. Subjects undergoing percutaneous revascularization had higher MMP-9 levels following revascularization than those subjects undergoing angiography without angioplasty.
CONCLUSIONS: Serial monitoring of MMPs indicates a differential subtype response to myocardial infarction and percutaneous revascularization. Results of this study indicate that MMP subtypes may play differing roles in the manifestation of acute coronary syndromes and response to revascularization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009768     DOI: 10.1111/j.1540-8183.2004.00289.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  12 in total

1.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

2.  The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats.

Authors:  Min Wu; Yu-Guang Li
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Expanded network of inflammatory markers of atherogenesis: where are we now?

Authors:  Seyed Hesameddin Abbasi; Mohammad Ali Boroumand
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

Review 4.  Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yu-Fang Jin; Merry L Lindsey
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

5.  Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis.

Authors:  Karyn M Austin; Nga Nguyen; Golrokh Javid; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2013-06-27       Impact factor: 5.157

Review 6.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

7.  Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.

Authors:  Giuseppe Derosa; Angela D'Angelo; Filippo Scalise; Maria A Avanzini; Carmine Tinelli; Emmanouil Peros; Elena Fogari; Arrigo F G Cicero
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

Review 8.  Matrix metalloproteases and PAR1 activation.

Authors:  Karyn M Austin; Lidija Covic; Athan Kuliopulos
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

9.  Acute coronary syndromes: from the laboratory markers to the coronary vessels.

Authors:  Palazzuoli Alberto; Iovine Francesca; Scali Chiara; Nuti Ranuccio
Journal:  Biomark Insights       Date:  2007-02-07

10.  Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.

Authors:  José A Páramo; José A Rodríguez Ja; Josune Orbe
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.